Plain-English translation of NCT06547736 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether SHR-A2102, SHR-A1904, or SHR-A1811—new types of cancer-fighting drugs called ADC drugs—work better when given alone or combined with other medications for advanced pancreatic cancer. The study will first test different doses to find the safest and most effective dose, then move to a larger phase to see how well the medication actually works.
Pancreatic cancer that has spread or cannot be removed surgically is very difficult to treat. This trial is exploring whether these new medications, possibly in combination with immunotherapy drugs, could help patients with this serious disease live longer and better.
You likely qualify if…
You likely don't qualify if…
You would receive one of the study medications either alone or in combination with other drugs, depending on which group you're assigned to. The study has two phases: first, doctors will test different doses to find the safest level, then move to a larger phase to measure how well the treatment works. You'll have regular visits for blood tests, scans, and check-ups to monitor how you're responding and watch for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China